SETD2 and cancer: While there is a benefit of using a more ‘targetted’ approach in reducing false positives, reducing the cut-off value comes with the risk of excluding potentially important CpGs that can provide new insights into the role of SETD2 in cancer and the methylation-gene regulation axis, which was an important focus of our study.